• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday

    10/30/23 10:19:29 AM ET
    $ALX
    $BGNE
    $CIFR
    $DAWN
    Real Estate Investment Trusts
    Real Estate
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALX alert in real time by email

    U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today’s session.

    • ImmunityBio, Inc. (NASDAQ:IBRX) shares rose 19.4% to $2.9600. The FDA recently accepted ImmunityBio's resubmission of its Biologics License Application for N-803 as complete.
    • Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) surged 18.5% to $12.03 after the company announced its study of patients with TGCT met its primary and secondary endpoint.
    • JinkoSolar Holding Co., Ltd. (NYSE:JKS) gained 16% to $30.01 following better-than-expected quarterly results.
    • Daqo New Energy Corp. (NYSE:DQ) climbed 15% to $26.82 following quarterly results.
    • Vitru Limited (NASDAQ:VTRU) gained 14.4% to $14.46. Vitru is expected to report its third quarter 2023 financial results on Nov. 09, 2023.
    • Lumentum Holdings Inc. (NASDAQ:LITE) gained 13.2% to $40.83 as the company announced plans to buy Cloud Light Technology for around $750 million.
    • Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) surged 12.5% to $11.45 after the company announced the FDA accepted its NDA for tovorafenib in relapsed or progressive pediatric low-grade glioma, granted priority review and assigned a PDUFA date of April 30, 2024.
    • XPO, Inc. (NYSE:XPO) rose 12.2% to $75.54 after the company reported better-than-expected third-quarter financial results.
    • HUTCHMED (China) Limited (NASDAQ:HCM) gained 12.2% to $20.73.
    • BeiGene, Ltd. (NASDAQ:BGNE) climbed 11.2% to $189.60. BeiGene recently said BRUKINSA received a positive recommendation from NICE in the UK for adult patients with chronic lymphocytic leukemia.
    • Cipher Mining Inc. (NASDAQ:CIFR) rose 10.8% to $3.68.
    • Western Digital Corporation (NASDAQ:WDC) gained 10.3% to $42.99 after the company reported first-quarter results and announced a plan to separate its HDD and Flash businesses.
    • NerdWallet, Inc. (NASDAQ:NRDS) rose 9.5% to $10.22.
    • Alexander's, Inc. (NYSE:ALX) climbed 8.8% to $194.99 following third-quarter results.
    • Spirit Realty Capital, Inc. (NYSE:SRC) rose 8.8% to $35.22 after Realty Income agreed to acquire the company in a $9.3 billion all-stock transaction.
    • Pagaya Technologies Ltd. (NASDAQ:PGY) gained 8.8% to $1.2200.
    • Zai Lab Limited (NASDAQ:ZLAB) climbed 8.5% to $25.50.
    • Chart Industries, Inc. (NASDAQ:GTLS) gained 7.7% to $118.43.
    • Viridian Therapeutics, Inc. (NASDAQ:VRDN) rose 7.7% to $13.33 as the company named Stephen Mahoney as new Chief Executive Officer. The company unveiled next generation FcRn inhibitor programs and announced a $185 million private placement financing.
    • TG Therapeutics, Inc. (NASDAQ:TGTX) gained 7.5% to $7.48.
    • Summit Therapeutics Inc. (NASDAQ:SMMT) rose 6.6% to $1.93.
    • SJW Group (NYSE:SJW) climbed 4.3% to $61.19 following strong quarterly results.

     

     

    Now Read This: Ethereum Tops This Key Level; Axie Infinity Emerges As Top Gainer

    Get the next $ALX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALX
    $BGNE
    $CIFR
    $DAWN

    CompanyDatePrice TargetRatingAnalyst
    Western Digital Corporation
    $WDC
    3/31/2026$340.00Mkt Perform → Outperform
    Bernstein
    JinkoSolar Holding Company Limited
    $JKS
    3/24/2026$28.50Sell → Buy
    Daiwa Securities
    Summit Therapeutics Inc.
    $SMMT
    3/16/2026$15.00Buy → Hold
    Jefferies
    NerdWallet Inc.
    $NRDS
    3/13/2026Equal-Weight → Underweight
    Morgan Stanley
    Lumentum Holdings Inc.
    $LITE
    3/12/2026$675.00Hold
    TD Cowen
    ImmunityBio Inc.
    $IBRX
    3/12/2026$13.00Buy
    BTIG Research
    Day One Biopharmaceuticals Inc.
    $DAWN
    3/10/2026$21.50Buy → Neutral
    H.C. Wainwright
    XPO Inc.
    $XPO
    2/11/2026$210.00Positive → Neutral
    Susquehanna
    More analyst ratings

    $ALX
    $BGNE
    $CIFR
    $DAWN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

    Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (SUPPL-11) with active ingredient UBLITUXIMAB-XIIY has changed to 'Approval' on 10/30/2024. Application Category: BLA, Application Number: 761238, Application Classification:

    10/31/24 4:38:40 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    April 30, 2024 - FDA Roundup: April 30, 2024

    For Immediate Release: April 30, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “A Milestone in Facilitating the Development of Safe and Effective Biosimilars,” by Sarah Yim, Director of the Office of New Drugs’ Office of Therapeutic Biologics and Biosimilars, Hilary Marston, M.D., M.P.H., and Patriz

    4/30/24 3:20:20 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    April 26, 2024 - FDA Roundup: April 26, 2024

    For Immediate Release: April 26, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “A Milestone in Facilitating the Development of Safe and Effective Biosimilars,” by Sarah Yim, Director of the Office of New Drugs’ Office of Therapeutic Biologics and Biosimilars, Hilary Marston, M.D., M.P.H., and Patriz

    4/26/24 3:10:22 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALX
    $BGNE
    $CIFR
    $DAWN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    XPO Schedules First Quarter 2026 Earnings Conference Call for Thursday, April 30, 2026

    GREENWICH, Conn., April 07, 2026 (GLOBE NEWSWIRE) -- XPO (NYSE:XPO) will hold its first quarter conference call and webcast on Thursday, April 30, at 8:30 a.m. Eastern Time. The company's results will be released earlier that morning and made available on www.xpo.com.Access information:Call toll-free from US/Canada: 1-877-269-7756International callers: +1-201-689-7817Live webcast online at: www.xpo.com/investorsA replay of the conference call will be available until May 30, 2026, by calling toll-free (from US/Canada) 1-877-660-6853; international callers dial +1-201-612-7415. Use the passcode 13759585. Additionally, the call will be archived on www.xpo.com/investors.About XPOXPO, Inc. (NYS

    4/7/26 4:05:00 PM ET
    $XPO
    Transportation Services
    Consumer Discretionary

    Pagaya Issues AAA-rated $600 Million Personal Loan ABS Transaction

    Consistent market demand led to the successful onboarding of four new institutional investors to the PAID platform, further diversifying the company's funding base. Since inception, Pagaya has generated $28.5 billion in ABS for personal loans to support its growing Partner Network. Pagaya Technologies LTD. (NASDAQ:PGY) ("Pagaya" or "the Company"), a global technology company delivering AI-driven product solutions for the financial ecosystem, today announced the closing of a $600 million AAA rated, personal loan ABS transaction (PAID 2026-2). A total of 27 unique investors participated in the personal loan securitization, with the majority returning from prior transactions, and desp

    4/6/26 8:30:00 AM ET
    $PGY
    Finance: Consumer Services
    Finance

    Lumentum to Announce Fiscal Third Quarter 2026 Financial Results on May 5, 2026

    Lumentum Holdings Inc. ("Lumentum") today announced that it will release its fiscal third quarter 2026 financial results on Tuesday, May 5, 2026, after the market closes. Lumentum will hold an audio webcast the same day at 2:00 p.m. PT/5:00 p.m. ET. A live audio webcast of the call and replay will be available in the Investors section of the Lumentum website at http://investor.lumentum.com. Analysts planning to participate in the interactive Q&A portion of the webcast are encouraged to pre-register: pre-registration link. The earnings press release will be posted at http://investor.lumentum.com under the "News Releases" section. Additional materials supporting the conference call and ea

    4/6/26 8:30:00 AM ET
    $LITE
    Telecommunications Equipment
    Telecommunications

    $ALX
    $BGNE
    $CIFR
    $DAWN
    SEC Filings

    View All

    SEC Form DEFA14A filed by XPO Inc.

    DEFA14A - XPO, Inc. (0001166003) (Filer)

    4/7/26 4:43:16 PM ET
    $XPO
    Transportation Services
    Consumer Discretionary

    SEC Form DEFA14A filed by XPO Inc.

    DEFA14A - XPO, Inc. (0001166003) (Filer)

    4/7/26 4:37:24 PM ET
    $XPO
    Transportation Services
    Consumer Discretionary

    SEC Form DEF 14A filed by XPO Inc.

    DEF 14A - XPO, Inc. (0001166003) (Filer)

    4/7/26 4:32:12 PM ET
    $XPO
    Transportation Services
    Consumer Discretionary

    $ALX
    $BGNE
    $CIFR
    $DAWN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fairmount Funds Management Llc bought $9,999,990 worth of shares (454,545 units at $22.00) (SEC Form 4)

    4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

    10/27/25 4:30:38 PM ET
    $VRDN
    Medical Specialities
    Health Care

    Director Xia Yu bought $9,999,983 worth of shares (533,617 units at $18.74) (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    10/23/25 9:06:30 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Co-Chief Executive Officer Duggan Robert W bought $499,983 worth of shares (26,680 units at $18.74) and was granted 14,247,597 shares, increasing direct ownership by 3% to 570,073,879 units (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    10/23/25 4:08:30 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALX
    $BGNE
    $CIFR
    $DAWN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Mumford Gregory J.D.

    4 - Cipher Digital Inc. (0001819989) (Issuer)

    4/7/26 6:18:52 PM ET
    $CIFR
    Finance: Consumer Services
    Finance

    SEC Form 4 filed by Edmondson Frazor Titus Iii

    4 - Zai Lab Ltd (0001704292) (Issuer)

    4/3/26 5:58:53 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Smiley Joshua L

    4 - Zai Lab Ltd (0001704292) (Issuer)

    4/3/26 5:59:18 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALX
    $BGNE
    $CIFR
    $DAWN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Western Digital upgraded by Bernstein with a new price target

    Bernstein upgraded Western Digital from Mkt Perform to Outperform and set a new price target of $340.00

    3/31/26 8:07:13 AM ET
    $WDC
    Electronic Components
    Technology

    JinkoSolar upgraded by Daiwa Securities with a new price target

    Daiwa Securities upgraded JinkoSolar from Sell to Buy and set a new price target of $28.50

    3/24/26 8:27:29 AM ET
    $JKS
    Semiconductors
    Technology

    Summit Therapeutics downgraded by Jefferies with a new price target

    Jefferies downgraded Summit Therapeutics from Buy to Hold and set a new price target of $15.00

    3/16/26 8:36:55 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALX
    $BGNE
    $CIFR
    $DAWN
    Leadership Updates

    Live Leadership Updates

    View All

    Lumentum to Join the S&P 500 Index

    Lumentum Holdings Inc. ("Lumentum"), a global leader in optical and photonic solutions, today announced that it has been selected to join the prestigious S&P 500 index. According to S&P Dow Jones Indices, Lumentum will be added to the benchmark index before the market opens on Monday, March 23, 2026. This transition marks a significant milestone for the company as it moves from the S&P MidCap 400 to the S&P 500, reflecting its substantial growth and corresponding increase in market capitalization. "Inclusion in the S&P 500 is a monumental achievement for our company and a credit to our global workforce," said Michael Hurlston, President and CEO. "It reflects our vital role in helping cust

    3/10/26 8:00:00 AM ET
    $LITE
    Telecommunications Equipment
    Telecommunications

    Vertiv Holdings, Lumentum Holdings, Coherent, and EchoStar Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

    NEW YORK, March 6, 2026 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices: NAPCO Security Technologies Inc. (NASD: NSSC) will replace Alexander & Baldwin Inc. (NYSE:ALEX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, March 13. An investor group comprised of MW Group and funds affiliated with DivcoWest and Blackstone Real Estate is acquiring Alexander & Baldwin in a deal that is expected to close soon, pending final closing conditions.The following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 will take effect before the market opens on M

    3/6/26 6:39:00 PM ET
    $AGX
    $AHRT
    $AIG
    Engineering & Construction
    Consumer Discretionary
    Real Estate
    Finance

    Cipher Welcomes Thomas Duda to the Company's Board of Directors

    NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Cipher Mining Inc. (NASDAQ:CIFR) ("Cipher" or the "Company"), a leading developer and operator of industrial-scale data centers, today announces the appointment of Thomas Duda to its Board of Directors. Mr. Duda has more than twenty years of real estate-focused investment experience, further strengthening the Board as Cipher executes its pivot to becoming a world leader in data center development and operations. Mr. Duda currently serves as Vice President of Real Estate at Henry Crown and Company, where he leads the firm's real estate investment and asset management activities, and is a member of the Investment and Management Committee. Previous

    2/11/26 4:05:00 PM ET
    $CIFR
    Finance: Consumer Services
    Finance

    $ALX
    $BGNE
    $CIFR
    $DAWN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by BeiGene Ltd.

    SC 13D/A - BeiGene, Ltd. (0001651308) (Subject)

    12/10/24 9:30:34 PM ET
    $BGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by BeiGene Ltd.

    SC 13D/A - BeiGene, Ltd. (0001651308) (Subject)

    12/4/24 4:05:33 PM ET
    $BGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lumentum Holdings Inc.

    SC 13G/A - Lumentum Holdings Inc. (0001633978) (Subject)

    11/14/24 7:53:37 PM ET
    $LITE
    Telecommunications Equipment
    Telecommunications

    $ALX
    $BGNE
    $CIFR
    $DAWN
    Financials

    Live finance-specific insights

    View All

    XPO Schedules First Quarter 2026 Earnings Conference Call for Thursday, April 30, 2026

    GREENWICH, Conn., April 07, 2026 (GLOBE NEWSWIRE) -- XPO (NYSE:XPO) will hold its first quarter conference call and webcast on Thursday, April 30, at 8:30 a.m. Eastern Time. The company's results will be released earlier that morning and made available on www.xpo.com.Access information:Call toll-free from US/Canada: 1-877-269-7756International callers: +1-201-689-7817Live webcast online at: www.xpo.com/investorsA replay of the conference call will be available until May 30, 2026, by calling toll-free (from US/Canada) 1-877-660-6853; international callers dial +1-201-612-7415. Use the passcode 13759585. Additionally, the call will be archived on www.xpo.com/investors.About XPOXPO, Inc. (NYS

    4/7/26 4:05:00 PM ET
    $XPO
    Transportation Services
    Consumer Discretionary

    Lumentum to Announce Fiscal Third Quarter 2026 Financial Results on May 5, 2026

    Lumentum Holdings Inc. ("Lumentum") today announced that it will release its fiscal third quarter 2026 financial results on Tuesday, May 5, 2026, after the market closes. Lumentum will hold an audio webcast the same day at 2:00 p.m. PT/5:00 p.m. ET. A live audio webcast of the call and replay will be available in the Investors section of the Lumentum website at http://investor.lumentum.com. Analysts planning to participate in the interactive Q&A portion of the webcast are encouraged to pre-register: pre-registration link. The earnings press release will be posted at http://investor.lumentum.com under the "News Releases" section. Additional materials supporting the conference call and ea

    4/6/26 8:30:00 AM ET
    $LITE
    Telecommunications Equipment
    Telecommunications

    Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease

    - REVEAL-1 met the primary endpoint of Q4W proptosis responder rate (PRR) with a highly statistically significant treatment effect - - Elegrobart Q4W and Q8W achieved clinically meaningful 54% and 63% PRR versus 18% placebo at week 24 - - Complete resolution of diplopia in 51% of patients treated Q4W versus 16% placebo at week 24 - - Elegrobart was generally well tolerated in both dose groups with low rates of hearing impairment - - REVEAL-2, a phase 3 clinical trial evaluating elegrobart in patients with chronic TED, is on track for topline readout in Q2 2026; BLA submission anticipated in Q1 2027 - - Viridian ended Q4 2025 with $875 million in cash; the company anticipates exist

    3/30/26 7:01:00 AM ET
    $VRDN
    Medical Specialities
    Health Care